Abstract
We performed population pharmacokinetic analysis of micafungin in adult patients treated with doses between 12.5 and 200 mg/day. Our analysis identified a breakpoint patient weight of 66.3 kg above which serum clearance increased by approximately 50%. Patients with weight >66.3 kg may need larger doses to achieve similar exposures to those <66.3 kg. However, the clinical implications are still unknown.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Body Weight
-
Echinocandins / administration & dosage*
-
Echinocandins / pharmacokinetics*
-
Female
-
Humans
-
Lipopeptides
-
Lipoproteins / administration & dosage*
-
Lipoproteins / pharmacokinetics*
-
Male
-
Metabolic Clearance Rate
-
Micafungin
-
Middle Aged
-
Serum / chemistry
Substances
-
Echinocandins
-
Lipopeptides
-
Lipoproteins
-
Micafungin